Safety and Efficacy of Atezolizumab Combined to Preoperative Radio-chemotherapy in Localized Rectal Cancer
Status:
Recruiting
Trial end date:
2021-04-01
Target enrollment:
Participant gender:
Summary
The study has a phase Ib and a phase II part. The phase Ib part of the study aims to
determine the safety and tolerance of administration at a fixed dosing of 1200 mg / 3 weeks,
concomitantly to the standard preoperative radio-chemotherapy.
The phase II part of the study aims to explore efficacy of atezolizumab in combination with
the standard preoperative chemo/radiotherapy in stage II and III rectal cancers.